Abstract 1542P
Background
Treatment options for patients with small cell lung cancer (SCLC) have substantially improved with the approval of the first two checkpoint inhibitors (CPI), atezolizumab (2019) and durvalumab (2020), for stage IV SCLC. How are patients with SCLC treated outside of clinical trials and how do these new treatments change the outcome in routine care in Germany?
Methods
CRISP is a prospective, multi-center clinical research platform that aims to understand the treatment reality of patients with lung carcinoma in Germany. Between September 2019 and April 2021 114 sites in Germany recruited more than 800 patients diagnosed with SCLC in all stages. In-depths patient and tumor characteristics, details about biomarker testing, treatments, outcome and patient-reported outcomes data are collected. Here we present first data on 411 patients with extensive disease (stage IV) SCLC followed until February 28, 2021. Updated data will be presented.
Results
Of the 411 patients, 55% were male. The median age at diagnosis was 66 years, 28% of the patients had a very good overall condition at diagnosis (ECOG-PS = 0). Most common first-line therapies were CARBO+ETO with atezolizumab (68%) or without (18%). Patients treated with atezolizumab were slightly younger (median 65 vs. 68 years), had less often comorbidities (83% vs. 95%) but more often metastases of the central nervous system (24% vs. 16%) than patients not receiving the CPI. At the time of this analysis, 35% of patients with a minimum follow-up of one year (n=176) had already received second-line treatment, 28% of patients died prior to second-line treatment, the remainder were still in first-line treatment or lost to follow-up. In these patients, median progression-free survival was 6.2 months (95% Confidence Interval 5.1-7.5 months), 48% of patients had died at database cut. The disease control rate (DRC) for completed treatments was 65%.
Conclusions
CRISP presents first real-life data of patients with SCLC in Germany, showing fast implementation of newly approved treatments and outcomes comparable to those in the pivotal trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGmbH.
Funding
AstraZeneca, MSD, Roche.
Disclosure
M. Sebastian: Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer-Ingelheim, Takeda, BMS, MSD, Merck Serono, Pfizer, Novartis, Lilly, Roche, Janssen, Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer-Ingelheim, Takeda, BMS, MSD, Merck Serono, Pfizer, Novartis, Lilly, Roche, Janssen, Amgen, GSK. M. Reck: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Beignene, Boehringer-Ingelheim, BMS, Merck, MSD, Mirati, Novartis, Janssen, Pfizer, Roche, Sanofi; Financial Interests, Institutional, Funding: BMS, Boehringer-Ingelheim; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, BeiGene, Boehringer-Ingelheim, BMS, Merck, MSD, Mirati, Novartis, Janssen, Pfizer, Roche, Sanofi. R.N. Fischer: Financial Interests, Personal, Invited Speaker: Roche, Boehringer Ingelheim; Financial Interests, Institutional, Funding: BMS, MSD. D.C.C. Christoph: Financial Interests, Personal, Advisory Role: AstraZeneca, Roche; Financial Interests, Personal, Funding: AstraZeneca, Roche. E. von der Heyde: Financial Interests, Institutional, Advisory Role: BMS; Financial Interests, Personal, Invited Speaker: BMS, AstraZeneca, Merck, Ipsen, Novartis, Boehringer-Ingelheim, Pierre Fabre; Financial Interests, Institutional, Funding: BMS, Novartis, Boehringer-Ingelhiem. P. Ludwig: Financial Interests, Institutional, Funding: Amgen, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Janssen, MSD, Lilly, Novartis, Pfizer, Roche, Takeda. A. Hipper: Financial Interests, Institutional, Funding: Amgen, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Janssen, MSD, Lilly, Novartis, Pfizer, Roche, Takeda. J. Hanselmann: Financial Interests, Institutional, Funding: AIO. T. Medinger: Financial Interests, Institutional, Funding: AIO. A. Binninger: Financial Interests, Institutional, Funding: AIO. M. Jänicke: Financial Interests, Institutional, Funding: AIO. P. Christopoulos: Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Takeda; Financial Interests, Institutional, Funding: Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Roche, Takeda. T.C. Gauler: Financial Interests, Personal, Advisory Role: AstraZeneca, BMS, Onkowissen.de; Financial Interests, Personal, Stocks/Shares: Bayer; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, BMS, Ipsen, Merck Servon, Roche. C. Waller: Financial Interests, Personal, Advisory Role: Mylan, Alvotech, Roche; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Chugai, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Takeda, Vifor. All other authors have declared no conflicts of interest.